Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study With Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone
This is a randomized two-arm parallel group study.
- Study group: PEI + long-acting somatostatin
- Control group: long-acting somatostatin alone
Aims of the study:
- Does treatment with PEI+ long-acting somatostatin prolong survival as compared to
treatment with long-acting somatostatin alone?
- Can time to tumour progression be extended in patients treated with PEI + long-acting
somatostatin as compared to treatment with long-acting somatostatin alone?
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
survival time
Christian Mueller, MD
Principal Investigator
Universitaetsklinik fuer Innere Medizin IV
Austria: Federal Ministry for Health and Women
HCC-327-2000
NCT00121914
October 2000
July 2005
Name | Location |
---|